Patents by Inventor Luigi Manenti

Luigi Manenti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION OF ANTI TIM-3 ANTIBODY MBG453 AND ANTI TGF-BETA ANTIBODY NIS793, WITH OR WITHOUT DECITABINE OR THE ANTI PD-1 ANTIBODY SPARTALIZUMAB, FOR TREATING MYELOFIBROSIS AND MYELODYSPLASTIC SYNDROME
    Publication number: 20230057071
    Abstract: Combination therapies comprising TIM-3 inhibitors and TGF-? inhibitors are disclosed. The combinations can be used to treat or prevent cancerous conditions and disorders, including myelofibrosis or myelodysplastic syndrome.
    Type: Application
    Filed: December 3, 2020
    Publication date: February 23, 2023
    Inventors: K. Gary J. VANASSE, Haiying SUN, Mirek DOSTALEK, Mikael RINNE, Anshu MARATHE, Luigi MANENTI, Claire FABRE, Fariba KHANSHAN
  • ENTPD2 ANTIBODIES, COMBINATION THERAPIES, AND METHODS OF USING THE ANTIBODIES AND COMBINATION THERAPIES
    Publication number: 20220348651
    Abstract: Provided herein are methods of treating cancer using an antibody or antigen-binding fragments thereof that specifically bind to human ENTPD2 protein, and compositions comprising these antibodies or antigen-binding fragments for use in the treatment of cancer. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies.
    Type: Application
    Filed: September 17, 2020
    Publication date: November 3, 2022
    Inventors: Michael DiDonato, Mirek Dostalek, Christoph Erkel, Javier Estrada Diez, Anna Galkin, Scott Martin Glaser, Klaus Felix Hartlepp, Yong Jia, Deborah A. Knee, Alexandra Kraus, Christian Cho-Hua Lee, Luigi Manenti, Sarah Michelle Rue, Jian Shi, Xenia Karola Wezler, Gabrielle Wong
  • COMBINATION THERAPY WITH ENTPD2 AND CD73 ANTIBODIES
    Publication number: 20220340685
    Abstract: Provided herein are combinations comprising an antibody or antigen-binding fragment thereof, e.g., a monoclonal antibody or antigen binding fragment thereof, that specifically binds to ENTPD2 (e.g., human ENTPD2 protein), and an antibody or antigen-binding fragment thereof, e.g., a monoclonal antibody or antigen binding fragment thereof, that specifically binds to CD73 (e.g., human CD73 protein), and methods of using these combinations.
    Type: Application
    Filed: September 17, 2020
    Publication date: October 27, 2022
    Inventors: Michael DiDonato, Mirek Dostalek, Christoph Erkel, Javier Estrada Diez, Anna Galkin, Scott Martin Glaser, Klaus Felix Hartlepp, Yong Jia, Deborah A. Knee, Alexandra Kraus, Christian Cho-Hua Lee, Luigi Manenti, Sarah Michelle Rue, Jian Shi, Xenia Karola Wezler, Gabrielle Wong
  • Combinations of FGFR4 inhibitors and bile acid sequestrants
    Patent number: 11229643
    Abstract: The present invention relates to a pharmaceutical combination comprising an FGFR4 inhibitor and a bile acid sequestrant, to the use of the pharmaceutical combination in the treatment of cancer, to the use of a bile acid sequestrant to reduce or mitigate side-effects associated with FGFR4 inhibition therapy.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: January 25, 2022
    Assignee: NOVARTIS AG
    Inventors: Robin Alec Fairhurst, Diana Graus Porta, Jacqueline Kinyamu-Akunda, Andreas Joerg Mahl, Luigi Manenti, Andreas Weiss, Armin Wolf, Kuno Wuersch
  • COMBINATIONS OF FGFR4 INHIBITORS AND BILE ACID SEQUESTRANTS
    Publication number: 20200261444
    Abstract: The present invention relates to a pharmaceutical combination comprising an FGFR4 inhibitor and a bile acid sequestrant, to the use of the pharmaceutical combination in the treatment of cancer, to the use of a bile acid sequestrant to reduce or mitigate side-effects associated with FGFR4 inhibition therapy.
    Type: Application
    Filed: November 1, 2017
    Publication date: August 20, 2020
    Applicant: NOVARTIS AG
    Inventors: Robin Alec FAIRHURST, Diana GRAUS PORTA, Jacqueline KINYAMU-AKUNDA, Andreas Joerg MAHL, Luigi MANENTI, Andreas WEISS, Armin WOLF, Kuno WUERSCH
  • DOSAGE REGIMENS FOR ANTI-TIM-3 ANTIBODIES AND USES THEREOF
    Publication number: 20200223924
    Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The antibody molecules can be used to treat or prevent cancerous or infectious conditions and disorders.
    Type: Application
    Filed: June 27, 2018
    Publication date: July 16, 2020
    Inventors: Andrew Marc Stein, Jian Xu, Luigi Manenti, Catherine Anne Sabatos-Peyton
  • COMBINATION THERAPY
    Publication number: 20200101077
    Abstract: The present disclosure relates to pharmaceutical products comprising a combination of (i) a MET inhibitor which is INC280 or a pharmaceutically acceptable salt or hydrate thereof and (ii) an EGFR inhibitor which is an monoclonal antibody such as cetuximab or panitumumab, which are jointly active in the treatment of proliferative diseases, corresponding pharmaceutical formulations, uses, methods, processes, commercial packages and related embodiments.
    Type: Application
    Filed: November 20, 2019
    Publication date: April 2, 2020
    Inventors: HUAIXIANG HAO, Xizhong Huang, Luigi Manenti, Angela Tam
  • Combination Therapy
    Publication number: 20170224692
    Abstract: The present disclosure relates to pharmaceutical products comprising a combination of (i) a MET inhibitor which is INC280 or a pharmaceutically acceptable salt or hydrate thereof and (ii) an EGFR inhibitor which is an monoclonal antibody such as cetuximab or panitumumab, which are jointly active in the treatment of proliferative diseases, corresponding pharmaceutical formulations, uses, methods, processes, commercial packages and related embodiments.
    Type: Application
    Filed: July 23, 2015
    Publication date: August 10, 2017
    Applicant: Novartis AG
    Inventors: Huaixiang Hao, Xizhong Huang, Luigi Manenti, Angela Tam
  • PREDICTIVE BIOMARKER FOR CANCER TREATMENT WITH ADCC-ENHANCED ANTIBODIES
    Publication number: 20130273032
    Abstract: The present invention is directed to methods for identifying which patients diagnosed with cancer will most benefit from treatment with an anti-cancer therapy comprising an ADCC-enhanced antibody.
    Type: Application
    Filed: February 28, 2013
    Publication date: October 17, 2013
    Inventors: Christian Gerdes, Claude Gimmi, Simon Hollingsworth, Luigi Manenti, Ruediger Rueger, Pablo Umana